GLPwatch
Acute kidney injury
3,612 FAERS reports across 8 drugs
Last updated 2026-05-28 15:46 UTCA sudden loss of kidney function that can cause waste to build up in the blood and make it hard for the body to keep the right balance of fluids.
Plain-language definition of the term.
FDA labels for GLP-1 drugs including Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Trulicity, Victoza, Wegovy, Xultophy, and Zepbound mention acute kidney injury in their adverse reactions and warnings sections.
AI summary of the sources below.
FAERS report counts (as of 2026Q1) reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
| Drug | FAERS reports | Quarter |
|---|---|---|
| Victoza | 1,074 | 2026Q1 |
| Byetta | 630 | 2026Q1 |
| Trulicity | 621 | 2026Q1 |
| Ozempic | 559 | 2026Q1 |
| Mounjaro | 328 | 2026Q1 |
| Bydureon | 222 | 2026Q1 |
| Xultophy | 101 | 2026Q1 |
| Rybelsus | 77 | 2026Q1 |
Mentioned in FDA labels
Research mentioning acute kidney injury (24)
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
- Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
- Acute Kidney Injury Associated With Semaglutide.
- Liraglutide ameliorates renal injury in streptozotocin‑induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor‑κB pathway.
- Liraglutide-induced acute kidney injury.
- Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model.
- Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling.
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.
- Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists.
- Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.
- Liraglutide promotes autophagy by regulating the AMPK/mTOR pathway in a rat remnant kidney model of chronic renal failure.
- Exenatide and renal failure.
- An experimental study of exenatide effects on renal injury in diabetic rats1.
- Liraglutide ameliorates gentamicin-induced acute kidney injury in rats via PGC-1α- mediated mitochondrial biogenesis: Involvement of PKA/CREB and Notch/Hes-1 signaling pathways.
- Liraglutide improves obesity-induced renal injury by alleviating uncoupling of the glomerular VEGF-NO axis in obese mice.
- The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study.
- GLP-1 agonist associated acute kidney injury: A case report and review.
- Exenatide induced acute kidney injury.
- [The protective effect of exenatide on the renal injury in diabetic rats].